Sanofi
SNY
$50.05
-$0.53-1.05%
NASDAQ
| 06/30/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | 44.39B | 38.85B | 38.50B | |
| Total Other Revenue | -- | 3.46B | 3.81B | 3.71B | |
| Total Revenue | -- | 47.85B | 42.66B | 42.21B | |
| Cost of Revenue | -- | 14.25B | 12.94B | 13.09B | |
| Gross Profit | -- | 33.59B | 29.72B | 29.12B | |
| SG&A Expenses | -- | 9.95B | 8.37B | 8.73B | |
| Depreciation & Amortization | -- | 1.89B | 1.73B | 1.90B | |
| Other Operating Expenses | -- | 3.94B | 4.58B | 4.08B | |
| Total Operating Expenses | -- | 38.00B | 34.91B | 34.92B | |
| Operating Income | -- | 9.84B | 7.75B | 7.30B | |
| Income Before Tax | -- | 7.60B | 5.11B | 4.65B | |
| Income Tax Expenses | -- | 1.36B | 847.46M | 708.26M | |
| Earnings from Continuing Operations | -- | 6.24K | 4.27K | 3.95K | |
| Earnings from Discontinued Operations | -- | 64.19M | 261.39M | 217.42M | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -62.97M | -46.49M | -28.76M | |
| Net Income | -- | 6.24B | 4.84B | 4.50B | |
| EBIT | -- | 9.84B | 7.75B | 7.30B | |
| EBITDA | -- | 13.28B | 11.02B | 10.57B | |
| EPS Basic | -- | 4.99 | 3.87 | 3.59 | |
| Normalized Basic EPS | -- | 0.78 | -- | -- | |
| EPS Diluted | -- | 4.98 | 3.86 | 3.58 | |
| Normalized Diluted EPS | -- | 0.78 | -- | -- | |
| Average Basic Shares Outstanding | -- | 5.00B | 5.00B | 5.00B | |
| Average Diluted Shares Outstanding | -- | 5.01B | 5.01B | 5.01B | |
| Dividend Per Share | -- | 4.18 | 4.05 | 4.05 | |
| Payout Ratio | -- | -- | -- | -- | |